Status:
COMPLETED
The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen
Lead Sponsor:
AstraZeneca
Conditions:
Allergic Asthma
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
AZD8848 is a new drug that is being tested for the treatment of asthma and allergic rhinitis (hayfever). This study will be in two parts and will include 59 asthmatic patients in total. The first part...
Eligibility Criteria
Inclusion
- FEV1 \> 70 % of predicted normal pre-bronchodilator
- Documented history of asthma
- Presence of allergic sensitivity
Exclusion
- Clinically relevant disease and/or abnormality (past or present), which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or influence the results of the study, or the patient's ability to participate in the study.
- Symptomatic allergic rhinitis
- Any clinical relevant abnormal findings in physical examination or assessment which may put the patient at risk because of participation in the study
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00999466
Start Date
October 1 2009
End Date
December 1 2011
Last Update
February 26 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
London, United Kingdom
2
Research Site
Manchester, United Kingdom